Stay informed with expert insights, trends, and best practices in life sciences compliance.
In qordata’s most recent post: A Quick Quiz To Check Your Compliance Analytics Acumen, Zafar Ahmed quotes Ishita Arora on realistic scope assumptions to make when designing one’s compliance/transparency program. We take that discussion a little further today by discussing how to better organize the pharma compliance workflow by dividing it in two phases: Reporting […]
Still unsure about introducing a compliance analytics program into your company? You’re not alone. Of the 9272* medical drug and device companies in the USA, only 1,481 submitted their CMS report in 2016, down from 1,579 in 2015. While for some, macro issues like M&A and CIAs may explain the lack of a report, other […]
Pharmaceutical companies do not want to keep doctors away. But even if they did, it would be easier (and riskier) than taking an apple a day. A lot riskier. Tiny typos can have huge consequences. Without meaning to, and often under pressure to meet submission deadlines, compliance/transparency professionals can make errors that increase their workload […]
CMS open payments reporting solution, qordata’s foremost solution for pharmaceutical spend analytics, helps drug and device manufacturers gain visibility into their spend data. With the publication of 2016 records by CMS on 30th June 2017, qordata has been amongst the first to share the industry’s most incisive insights in this blog. Data from 2016’s records […]
In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, How to “Determine the Relationships of Different Global Disclosure Requirements,” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private-sector synergy. Or […]
The synergy between pharma associations may never materialize. It may even backfire. We will elaborate on this in an upcoming post, with the real-life case of pharma disclosure in Germany. Today, we discuss how public interest has surfaced as a surprisingly powerful ally in the pharma transparency movement. Before exploring the ‘whats’ and ‘hows’, we […]
Your usage of this site constitutes acceptance of our Terms of Use & Data Policy. The material on this say may not be reproduced, distributed, transmitted, cached, or otherwise used without qordata’s consent. qordata is an Equal Opportunity Employer. All qualified individuals are accepted as employees and will receive consideration for employment without regard to race, gender, color, age, religion, sex, national origin, protected veteran status, or any other characteristic protected under federal, state, or local law.
© qordata 0. All rights reserved | Sitemap | Privacy Policy | Terms of Use